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ABSTRACT 
Background: Pleural infection is associated with a high morbidity and mortality. Development of a 
validated clinical risk score at presentation to identify those at high risk would enable triage of 
patients and may help inform early management strategies.  
 
Method: A clinical risk score was derived, based on data from patients entering the multi-centre 
UK pleural infection trial (MIST1, n=411). From 22 baseline clinical characteristics model selection 
was undertaken to find variables predictive of poor clinical outcome. The outcomes were mortality 
at 3 months (primary), need for surgical intervention at 3 months and time from randomisation to 
discharge. The derived scoring system (RAPID) was validated using patients enrolled in a 
subsequent UK multi-centre pleural infection trial (MIST2, n=191). 
 
Results: Age, urea, albumin, hospital-acquired infection, and non-purulence predicted poor 
outcome. Using this (the RAPID) score, patients were stratified into low- (0-2), medium- (3-4) and 
high-risk (5-7) groups. Using the low-risk group (score 0-2) as a reference, a RAPID score 3-4 and 
>4 was associated with an odds ratio (OR) of 24.4 (95% CI=3.1-186.7; p=0.002), and 192.4 
(95% CI=25.0-1480.4; p<0.001) respectively for death at 3 months. In the validation (MIST2) 
cohort, a medium-risk RAPID score was non-significantly associated with mortality (OR 3.2, 95% 
CI=0.8-13.2; p=0.11) and a high-risk score was associated with increased mortality (OR 14.1, 
95% CI=3.5-56.8; p<0.001). Duration of hospitalisation was associated with increasing RAPID 
score: score 0-2, median duration=7, IQR 6 to 13; score>5, median duration=15, IQR 9 to 28, 
p=0.08.  
 
Conclusion: The RAPID score may permit risk-stratification of patients with pleural infection at 
presentation and may be useful in guiding initial management.  
  
 
Abstract word count: 249 
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INTRODUCTION 
Pleural infection is increasing in incidence in both paediatric1-3 and adult4-6 populations, 
and is currently estimated to affect more than 65,000 patients per year in the United States 
and the United Kingdom7. These infections carry a significant health burden; mortality is 
between 10 and 20%5,8-10, approximately one third fail “medical management” and require 
surgical drainage5,10, 25% of patients require a hospital admission lasting more than one 
month10,11 and health care costs are estimated at around US$5000 per patient12,13 which equates 
to ~US$320 million per year (UK & US).  
  Standard treatment for involves appropriate antibiotics and drainage of infected pleural 
fluid/pus with an intrapleural catheter 11,14. More complex surgical drainage techniques (e.g. video 
assisted thoracoscopic surgical (VATS) drainage, open thoracotomy with decortication, rib 
resection and open drainage11,14) are advocated in patients with a poor response to initial 
treatment. A large cohort of 4,424 cases5 and other small surgical series15-19 suggest effective 
surgical drainage may be associated with improved outcome in selected patients. Early surgical 
intervention may thus be appropriate for high-risk patients. Although surgery has been advocated 
as initial treatment for all patients with pleural infection19-21, evidence to support the unselected 
use of surgery in all patients is lacking. Two moderate sized paediatric clinical trials showed no 
clinical benefit and greater cost from this approach12,22 and two small adult randomised trials did 
not use robust outcome methodologies23,24. Surgical thoracic procedures are associated with 
anaesthetic and perioperative risks25, and thoracotomy causes substantial post-operative pain26 up 
to 3 years after operation27. 
   Thus, surgery is a vital treatment option in pleural infection, but one which may be best 
used in selected patients. Recent evidence from a randomised placebo controlled trial28 suggests 
that a combination of intrapleural DNase and fibrinolytic improves radiology and may be 
associated with reduced hospital stay, reduced infection and reduced surgical rates. However, the 
drug treatment cost for this intervention is significant. A reliable and sensitive clinical prediction 
model of poor outcome in pleural infection would enable clinicians to triage patients in terms of 
risk, and might enable targeting of more aggressive and expensive therapies to patients with the 
poorest outcomes. To date, there are no robust validated methods for selecting high risk patients 
at presentation in pleural infection.  
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A cohort study performed in which clinical care was based on structured treatment guidelines9 in 
85 sequential patients assessed whether the generally accepted baseline predictors reliably 
identified patients at high risk. Only pleural fluid purulence had predictive power for a poor 
outcome, and this was insufficiently sensitive and specific to be of clinical value9. This finding was 
later confirmed in a second study29, in which predictors of residual pleural scarring were identified, 
although this was not associated with clinical disability. 
  Thus the traditionally used predictors of outcome in pleural infection have not been borne 
out in clinical studies specifically designed to assess their use. This study was conducted to derive 
a clinical risk score using baseline characteristics able to predict poor outcome, and then to 
validate this prediction model in a subsequent cohort of patients with pleural infection. 
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METHODS 
Study design 
This study used data from two randomised trials of intrapleural agents for the treatment 
of pleural infection10,28 diagnosed according to identical and standard clinical criteria (see 
below). 
The initial model derivation was conducted using baseline clinical and outcome data from 
the MIST1 trial10, a placebo controlled randomised trial assessing the use of intrapleural 
streptokinase which recruited 454 patients from 54 UK centres from 2002 to 2004. The derived 
model was then separately validated using baseline clinical and outcome data from MIST228, a 
randomised controlled trial assessing the use of intrapleural DNase and tPA, in which 210 
patients were recruited from 11 UK centres between 2005 to 2008, which demonstrated a 
significant improvement in the primary outcome measure (radiographic improvement) for the 
combination treatment compared to placebo.  
Full trial details and protocols are available with the original publications10,28 and 
included protocol recommendations on type and duration of antibiotic therapy, and intrapleural 
catheter use.  
 
Subjects enrolled 
Patients in both studies were included if they had clinical evidence of infection and 
fulfilled any of the following criteria; pleural fluid that was macroscopically purulent, or positive 
on culture for bacterial infection, or positive for bacteria on Gram staining, or pleural fluid that 
had a pH of <7.2 (measured using blood gas analyser). Evidence of infection was assessed by 
the recruiting physician on the basis of fever and elevated serum inflammatory markers such as 
C-reactive protein or white-blood count.  
Study exclusion criteria for both studies were identical and are listed in the online 
supplement.  
 
Trial outcomes 
The outcomes used in the model construction and derivation phase of the study were 
those considered clinically important: mortality at 3 months post randomisation, hospital stay 
6 of 24 
from randomisation to discharge to home / convalescent care and requirement for surgical 
intervention at 3 months. For model selection, the outcome of mortality at 3 months was 
considered decisive.  
 
Data analysis  
Model Derivation 
 Model selection was undertaken using the MIST1 cohort (in 411 / 454 (90.5%), in 
patients in whom baseline data of potential predictive value was present to find variables 
predictive of a poor clinical outcome (see online supplement for a full list of variables 
considered). Backwards selection with a p-value of 0.05 was used to find variables associated 
with mortality at 3 months, surgical intervention at 3 months, and hospital stay, with a 
separate model used for each outcome. Surgery and time in hospital were also assessed in 
patients who were less than 70 years of age to assess for a differential age effect. A subset of 
variables shown to be predictive of poor outcome were chosen to form the basis of the risk 
score. Variables were chosen based on the strength of association, clinical plausibility and ease 
of data collection at baseline for a potential predictive model. Effects of intrapleural treatments 
(streptokinase or tPA / DNase) were not modelled as baseline covariates were likely to be well 
balanced between treatment arms (due to randomisation) therefore preventing bias by ignoring 
treatments, and allowing more generalisable results. Multiple imputation using chained 
equations30 was used for patients with missing baseline variables, and 10 imputations were 
used. Fractional polynomials were used for continuous predictors31. Risk stratification according 
to the model was planned in to low, intermediate and high groups, with the lowest risk groups 
acting as the baseline comparator.  
   
Model Validation 
 The risk score derived from the MIST1 cohort was validated using patients from the 
MIST2 cohort. This was achieved by MIST2 patients into low, intermediate, and high risk groups 
according to the risk score derived from MIST1, and assessing mortality and surgery at 3 
months, and time to discharge within these groups. Overall survival was assessed using a Cox 
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model. Missing baseline variables used in calculating the risk score were handled using 
sensitivity analyses, assuming best and worst-case scenarios for each missing variable.  
 
Ethical Approval and Registration 
 Ethical and regulatory approval for each study was obtained before recruitment 
commenced and each trial was registered. For full details of registration, chest tube treatment 
and antibiotic management, please see the original publications10,28.  
 
8 of 24 
RESULTS 
Patients and data completeness 
The trial flow chart combining patients from both studies is presented in Figure 1. The 
baseline demographic, clinical and microbiological characteristics of participants in the 
combined trial populations and degree of data completeness for the purpose of this study are 
presented in Table 1. Mortality at 3 month data (primary outcome) was available in 617 / 621 
(99%) patients and secondary outcomes (surgery at 3 months and hospital stay from 
randomisation) were available in 614 / 621 (99%) patients and 617 / 621 (99%) patients 
respectively. Derivation of the predictive model was conducted in 411/454 patients and 
validation of the model was undertaken in 191 / 210 (91%) patients.   
 
Results - Predictive modelling 
Parameters selected and predictive of the specified outcomes using the MIST1 dataset 
(n=411) are summarised in the online supplement. Age >70, hospital (as opposed to 
community acquired) infection and urea >8mmol/L were all strongly associated with increased 
mortality at 3 months. Pleural fluid purulence, the presence of joint disease as a comorbidity, 
diastolic blood pressure (>70mmHg), and albumin >27mmol/L were associated with a 
decreased risk of mortality at 3 months.  
The only variable predictive of surgery at 3 months was age >70 years, associated with 
a decreased chance of surgery. Initial drain insertion conducted by a radiologist and serum 
albumin >27mmol/L were associated with a decreased length of hospital stay. Urea >8mmol/L, 
hospital acquired infection, and the presence of cardiac disease as a comorbidity were 
associated with increased length of stay. 
 
Creation of a predictive Model 
On the basis of the results above, Renal profile (urea) / Age / Purulence of pleural fluid 
/ Infection Source (hospital versus community) and Dietary factors (albumin) at baseline were 
used as predictors to form a scoring system (“RAPID”). Other variables (see online supplement) 
predictive of outcome were not included from the predictive modelling stage to maintain a 
clinically applicable and practical scoring system (Table 2). As the mortality odds ratios were 
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higher for Age and Renal profile, these were given a score out of 3 in the final scoring system. 
To aid clinical use of the RAPID score, patients were stratified according to score in to low-risk 
(score 0-2), medium-risk (score 3-4) and high-risk (score 5-7) groups (Table 2). The estimated 
odds ratios from each individual parameter derived in the prediction model are presented in 
Table 3.  
  Using the derived RAPID risk categorisation (low / medium / high) in the MIST1 cohort, 
mortality at 3 months in the low risk (reference) group was 1% (1/186), compared to 12% 
(14/121) in the medium risk group (OR 24.4, 95% CI 3.1 to 186.7, p=0.002) and 51% (26/51) 
in the high risk group (OR 192.4, 95% CI 25.0 to 1480.4, p<0.001).  For overall survival, the 
hazard ratio was 11.87 in the medium risk group (95% CI 4.16 to 33.85, p<0.001), and 48.27 
in the high risk group (95% CI 16.98 to 137.20, p<0.01).  
Median time to hospital discharge in the low risk group was 10 days (IQR 7 to 16), 
compared with 15 days (IQR 10 to 30) in the medium risk group(p<0.001), and 18 days (IQR 9 
to 26) in the high risk group (p<0.001).  
Data on missing variables and sensitivity analyses are presented in the online 
supplement. These analyses demonstrated no important differences using best or worst case 
scenarios in the predictive outcomes.  
 
Model validation results (MIST2 cohort) 
Assessment of the RAPID score in the MIST2 cohort demonstrated albumin (OR 2.8, 
95% CI 1.1 to 7.0, p=0.04) and urea (OR for highest category 3.96, 95% CI 1.7 to 9.4, 
p=0.002) as significant predictors of mortality at 3 months. Age (OR for highest category 4.66, 
p=0.07), infection source (OR=1.71, p=0.41), and purulence (OR=2.05, p=0.22) also showed 
strong effects but did not reach statistical significance (see online supplement).  
Validation of the risk categorisation in the MIST2 cohort demonstrated mortality of 3% 
(3/97) in the low risk (reference) group, 9% (6/65) in the medium risk group (OR 3.2, 95% CI 
0.8 to 13.2, p=0.11) and 31% (9/29) in the high risk group (OR 14.1, 95% CI 3.5 to 56.8, 
p<0.001) (Table 4). For overall survival, the hazard ratio was 4.69 in the medium risk group 
(95% CI 1.27 to 17.34, p=0.02) and 17.37 in the high risk group (95% CI 4.94 to 61.02, 
p<0.001). Overall mortality is presented as survival curves in Figure 2.  
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  For hospital stay, the median time to hospital discharge in the low risk group was 7 days 
(IQR 6 to 13), compared with 10 days (IQR 8 to 18) in the medium risk group (p=0.42), and 
15 days (IQR 9 to 28) in the high risk group (p=0.08).  
Sensitivity analyses were conducted using the method above and are presented in the 
online supplement, demonstrating no important differences using best or worst case scenarios. 
The receiver operating characteristics analysis for mortality at 3 months according to the RAPID 
score demonstrated an AUC of 0.88 (95% CI 0.84-0.93) for the derivation cohort and an AUC 
of 0.80 (95% CI 0.69-0.82) for the validation cohort (Figure 3) and for surgery at 3 months, an 
AUC of 0.36 (95% CI 0.28 to 0.43) for the derivation cohort and an AUC=0.50 (95% CI 0.39 to 
0.61) for the validation cohort (Figure 4).  
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DISCUSSION 
To our knowledge this is the first prognostic risk model for patients with pleural infection 
derived from data obtained from one cohort that has then been validated in a second cohort. Of 
22 baseline characteristics recorded at the time of initial presentation, five were strongly 
independently associated with poor outcome.  
The risk model developed gave more weighting to both age and urea in light of their 
high odds ratios for mortality, with the other three variables scoring the same. Each patients’ 
RAPID score therefore ranged between 0 - 7 with low risk patients (scoring 0-2) having a 1-3% 
mortality at 3 months, compared with 31-51% for high risk patients (scoring 5-7). This risk 
stratification at baseline, if validated in prospective studies, is a potentially important tool for 
the treating physician, with the potential to identify those at high risk at presentation, 
facilitating earlier discussions about aggressive management strategies while the patient is still 
well enough to receive them.  
Unsurprisingly, there are similarities with the widely used CURB-65 risk model, used for 
adults presenting to hospital with community acquired pneumonia32. Markers of poor outcome 
(confusion, urea>/=8mmol/L, respiratory rate >/=30/min, low blood pressure and age 
>/=6532) are similar to those found in our study in patients with pleural infection. Low albumin 
was also identified as a risk factor of poor outcome in the CURB-65 study. However, this 
variable was not included in the final model, due to concerns that this test is not routinely 
available. Although it may be suggested that the RAPID score may simply reflect the CURB 
score in these patients, it is increasingly recognised that pleural infection and pneumonia are 
different biological and microbiological processes33, with distinctly different outcomes.  
Low albumin  and poor nutritional status have long been associated with poor prognosis 
in pleural infection11, and age is a strong predictor of poor outcome in pleural infection, with 
previous series showing a strong correlation between increasing age and mortality 6,8. In our 
study, increased age was associated with a lower likelihood of undergoing surgical treatment 
despite the higher mortality associated with this age group. This may represent a lack of 
willingness to use surgical intervention in older populations, despite outcomes being worse. The 
ROC curve analysis demonstrates that while the RAPID prediction rule appears to predict 
mortality at 3 months (AUC 0.80 in the validation cohort), the predictive power for surgery at 3 
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months is poor (AUC 0.50), and this may be related to the most ill patients not being offered 
surgical treatment. Further investigation of this potential signal is now required.  
  A British Thoracic Society retrospective study on pleural infection found initial pleural fluid 
results were not predictive of poor outcome. Low albumin was however, associated with increased 
mortality8. Fluid purulence has been highlighted previously as a possible predictor of poor 
outcome9. In our study, we found the opposite to be the case, with non-purulence being a 
significant risk of poor outcome. Although this seems counter-intuitive, it may be explained by the 
clinical observation that frankly purulent effusions tend to have fewer loculations and therefore 
may be more likely to drain than non-purulent highly loculated collections.  
 Pleural infection remains common with recently reported studies reporting sharp 
increases in incidence1,2,6, and its associated mortality and morbidity remain high and has not 
improved over recent decades6,11. There is some evidence that delays in prompt and 
appropriate treatment subsequently result in more invasive interventions, leading to a more 
prolonged in hospital recovery and poorer outcomes 14,34. The RAPID score should help the 
clinician identify those likely to have a poor outcome at presentation; high scoring patients, 
scoring 5-7, have at least a 30% chance of dying in the following 12 weeks. It also informs the 
clinician of the increased likelihood of a prolonged hospital stay. These patients are likely to be 
best served by addressing their nutritional status immediately and consideration given to 
whether earlier more definitive surgical management is appropriate. Although it has been 
shown that delay in surgical referral can result in VATS surgery needing to be converted to 
thoracotomy and more formal decortication19,20, this needs to be the subject of specific further 
studies.  
There were some limitations in the development of the prognostic model. Previous 
research has shown that prognostic models developed on small datasets using backward 
selection methods tend to overstate the effect size of the variables included in the model35. 
However, the effect size for individual variables is not used to calculate the RAPID score, as all 
variables are assigned the same score (with the exception of the age and urea variables). And, 
in spite of the above limitations, validation of the RAPID score using the MIST2 dataset did find 
the chosen model to be predictive of poor outcome. A further potential limitation is the 
recruitment of patients for this study from randomised trials with specific inclusion and 
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exclusion criteria, which is not ideal for the development of prognostic models. However, the 
inclusion and exclusion criteria in the MIST110 and MIST228 studies closely reflect the normal 
population of pleural infection, and this is therefore not likely to be an unrepresentative sample.    
A further large prospective validation study is now required to evaluate if RAPID is a 
reliable and sensitive clinical prediction model of poor outcome in pleural infection. This would 
then enable clinicians to target aggressive and more expensive therapies to patients with the 
poorest outcomes in pleural infection. 
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TABLES 
 MIST1 (n=411) MIST2 (n=210) 
 Result Missing (n, %) Result Missing (n, %) 
Baseline Demographics 
Age (mean, SD) 59.7 (17.8) 0 (0) 58.8 (18.1) 0 (0) 
Male (n, %) 299 (72.7) 0 (0) 151 (71.9) 0 (0) 
Hospital-acquired 
infection (n, %) 
46 (11.3) 4 (1.0) 28 (13.3) 0 (0) 
Symptoms >=15 days 
prior to randomisation 
(n, %)) 
200 (49.9) 10 (2.4) 84 (41.0) 5 (2.3) 
Drain inserted by a 
radiologist (n, %) 
216 (53.5) 7 (1.7) Not collected Not collected 
% of hemithorax 
occupied with pleural 
fluid (mean, SD) 
n/a n/a 40.5 (23.5) 0 (0) 
Loculation (n, %) Not collected Not collected 192 (91.4) 0 (0) 
Pleural fluid characteristics 
Purulence (n, %) 339 (82.5) 0 (0) 102 (48.6) 0 (0) 
Gram stain (n, %) 88 (25.1) 60 (14.6) 10 (4.8) 3 (1.4) 
Culture (n, %) 64 (18.2) 60 (14.6) 15 (7.3) 4 (1.9) 
Gram stain or culture (n, 
%) 
105 (29.4) 54 (13.1) 21 (10.2) 4 (1.9) 
Antibiotics (n, %) 346 (85.2) 5 (1.2) 192 (91.9) 1 (0.5) 
Acidic Ph (mean, SD) 6.8 (0.4) 182 (44.3) 6.9 (0.3) 75 (35.7) 
Investigations at baseline 
WCC (mean, SD) 15.6 (7.1) 24 (5.8) 15.4 (6.9) 3 (1.4) 
CRP (median, IQR) 164  
(83 to 244) 
81  
(19.7) 
160  
(119 to 220) 
14  
(6.7) 
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Urea (median, IQR) 5.1  
(3.7 to 8.1) 
21  
(5.1) 
5.0  
(3.4 to 7.6) 
13  
(6.2) 
Albumin (mean, SD) 27.7 (6.9) 46 (11.2) 31.5 (7.8) 6 (2.9) 
Diastolic BP (mean, SD) 69.9 (11.7) 57 (13.9) 71.2 (11.8) 28 (13.3) 
Systolic BP (mean, SD) 124.9 (21.2) 57 (13.9) 126.1 (22.1) 27 (12.9) 
Creatinine  (median, 
IQR) 
79 (67 to 97) 17 (4.1) 78 (66 to 97) 33 (15.7) 
Co-morbid illnesses 
Respiratory problems (n, 
%) 
76 (18.7) 4 (1.0) 51 (28.3) 30 (14.3) 
Cardiac problems (n, %) 110 (27.0) 4 (1.0) 56 (30.6) 27 (12.9) 
Alcohol problems (n, %) 40 (9.8) 4 (1.0) 23 (12.7) 29 (13.8) 
Diabetes (n, %) 43 (10.6) 4 (1.0) 29 (16.0) 29 (13.8) 
Neurological problems 
(n, %) 
31 (7.6) 4 (1.0) 21 (11.5) 28 (13.3) 
  
Table 1. The baseline characteristics of the patients in each of the trials, including the amount 
of missing data for each parameter.  
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Parameter Measure Score 
Renal Urea             
                    
<5mmol/L             
5-8 mmol/L 
>8 mmol/L 
0 
1 
2 
Age Age              
                   
<50 years            
50-70 years  
>70 years 
0 
1 
2 
Purulence of 
pleural fluid 
Purulent 
Non-purulent 
0 
1 
Infection Source Community acquired  
Hospital acquired  
0 
1 
Dietary Factors Albumin       > or = 27mmol/L                 
<27mmol/L 
0 
1 
Risk categories Score 0-2 
Score 3-4 
Score 5-7 
Low risk 
Medium-Risk 
High Risk 
 
Table 2. Scoring system (“RAPID”) derived from the initial prediction model using baseline 
characteristics. Each patient can obtain a score from 0 to 7.  
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 % died 3 
months 
Odds 
Ratio 
95% CI p-value 
Age (years) 
        <50 (ref) 1/125 (1) n/a n/a 
<0.001         50-70 7/142 (5) 6.81 3.0 to 15.3 
        >=70 41/141 (29) 25.63 6.5 to 100.8 
Albumin 
        >=27 (ref) 15/207 (7) n/a n/a 
0.008 
        <27 26/155 (17) 2.25 1.2 to 4.1 
Urea 
        <5 (ref) 6/184 (3) n/a n/a 
<0.001         5-8 5/104 (5) 2.68 1.6 to 4.7 
        >=8 33/99 (33) 6.53 2.3 to 18.5 
Infection 
        -community (ref) 36/358 (10) n/a n/a 
0.03 
        -hospital 12/46 (26) 2.87 1.1 to 7.3 
Purulence 
        -purulent (ref) 37/338 (11) n/a n/a 
0.04 
        -non-purulent 12/70 (17) 2.61 1.0 to 6.7 
 
Table 3. Parameter estimates predicting mortality at 3 months from the MIST1 (n=408) cohort 
using the individual variables in the RAPID score. “Ref” refers to the reference category for each 
parameter. Although the presence of joint disease was significantly associated with outcome, 
the numbers of patients with joint disease (10%) was small, the predictive value of this 
parameter poor (OR 0.23, 95% CI) and this parameter had poor biological plausibility; this was 
not therefore included in the final model.  
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 Mortality at 3 
months (%) 
OR 95% CI p-value 
MIST1 (n=411) 
Low risk, score  
0-2 (ref) 
1/186 (1) n/a n/a n/a 
Medium risk, 
score 3-4 
14/121 (12) 24.41 3.14 to 186.65 0.002 
High risk, 
score >=5 
26/51 (51) 192.40 25.01 to 1480.41 <0.001 
MIST2 (n=191) 
Low risk, score  
0-2 (ref) 
3/97 (3) n/a n/a n/a 
Medium risk, 
score 3-4 
6/65 (9) 3.19 0.77 to 13.23 0.11 
High risk, 
score >=5 
9/29 (31) 14.1 3.50 to 56.78 <0.001 
 
Table 4. Mortality by RAPID risk category in the MIST1 and MIST2 cohorts. “Ref” refers to the 
reference category for each cohort.  
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Figure 1 – flowchart of patient numbers in the MIST1 (exploratory) and MIST2 (validation) 
datasets. * = at 3 months. 
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Figure 2. Survival curves for the MIST1 and MIST2 cohort of patients according to the derived 
RAPID scoring system.  
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Figure 3. ROC analysis for the derived RAPID score in the MIST1 (left panel) and MIST2 (right 
panel) cohorts for the outcome of mortality at 3 months.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. ROC analysis for the derived RAPID score in the MIST1 (left panel) and MIST2 (right 
panel) cohorts for the outcome of surgery at 3 months. 
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